Calcium channel blockers are among the first-line drugs for treatment of hypertension (HTN). S-amlodipine (S-AM), an S-enantiomer of amlodipine, is available in India and in other countries like China, Korea, Russia, Ukraine, and Nepal. Being clinically researched for nearly two decades, we performed in-depth review of S-AM. This review discusses clinical evidence from total 42 studies (26 randomized controlled trials, 14 observational studies, and 2 meta-analyses) corroborating over 7400 patients treated with S-AM. Efficacy and safety of S-AM in HTN in comparison to racemic amlodipine, used as monotherapy and in combination with other antihypertensives, efficacy in angina, and pleiotropic benefits with S-AM, are discussed in this review.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985099PMC
http://dx.doi.org/10.1155/2018/8681792DOI Listing

Publication Analysis

Top Keywords

racemic amlodipine
8
s-am
5
s-amlodipine isomer
4
isomer difference-time
4
difference-time shift
4
shift racemic
4
amlodipine calcium
4
calcium channel
4
channel blockers
4
blockers first-line
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!